share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

輝瑞 | 4：持股變動聲明-董事 NARAYEN SHANTANU
美股sec公告 ·  04/26 13:28
Moomoo AI 已提取核心訊息
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
輝瑞公司 [PFE] 的舉報人尚塔努·納拉延於2024年4月25日參與了一筆交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和交易後的持股情況。因此，該事件對納拉延持股和輝瑞整體市場地位的影響尚不清楚。
輝瑞公司 [PFE] 的舉報人尚塔努·納拉延於2024年4月25日參與了一筆交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和交易後的持股情況。因此，該事件對納拉延持股和輝瑞整體市場地位的影響尚不清楚。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息